Patients undergoing noncardiac surgery are at risk of adverse perioperative and long-term outcome. When considering a patient for noncardiac surgery, a careful preoperative clinical risk evaluation and subsequent risk-reduction strategies are essential to reduce postoperative complications. To assist physicians with decision making, clinical guidelines are developed. The aim of clinical guidelines is to improve patient care by providing recommendations about appropriate healthcare in specific circumstances. Development of clinical guidelines is an important component in improving the quality of care. By translating the best available scientific evidence into specific recommendations, guidelines can serve as a useful tool to achieve effective and efficient patient care. In 2009, the first European Society of Cardiology guidelines on perioperative care were developed. This decisionmaking process integrates clinical markers, early coronary evaluation, functional capacity, and the type of surgery involved.
In Europe, with an overall population of approximately 490 million, crude estimates of 7 million major surgical procedures are conducted annually. Cardiac events, such as myocardial infarction (MI) and cardiac death, are a major cause of perioperative morbidity and mortality in these patients. After major surgery, the incidence of cardiac death varies between 0.5% and 1.5%, with nonfatal cardiac complications ranging between 2% and 3.5%. Although the perioperative event rate has declined over the past decades as a result of achievements in anesthesio logical and surgical techniques, perioperative cardiovascular complications remain a significant problem. Therefore, appropriate preoperative cardiac risk assessment and implementation of proper risk reduction strategies are of imminent importance in the perioperative setting. The recently published new guidelines of the European Society of Cardiology (ESC) on perioperative cardiac care provide valuable tools for daily clinical practice for the physicians.
1 In this review, the most important recommendations for preoperative cardiac risk assessment and perioperative cardiac management in noncardiac surgery are highlighted.
In general, the risk of perioperative complications depends on the condition of the patient prior to surgery, the prevalence of comorbidities, and the severity, type, and duration of the surgical procedure. Especially patients with documented or hidden coronary artery disease (CAD) undergoing procedures that are associated with prolonged hemo dynamic and cardiac stress are prone to cardiac complications. Perioperative MI (PMI) is one of the most important predictors of short-and long-term morbidity and mortality associated with noncardiac surgery. The highest incidence of PMI is within the first 3 days after
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European Society of Cardiology 2009 guidelines for preoperative cardiac risk assessment and perioperative cardiac management in noncardiac surgery capacity, i.e., a MET <4, is equivalent to the inability to climb 2 flights of stairs or run a short distance. Patients with a good functional capacity (MET >4) might be scheduled for surgery, providing that patients with CAD or risk factor(s) receive statin therapy and a titrated low-dose β-blocker regimen prior to surgery. Patients with a moderate or low functional capacity are at an increased risk of postoperative events. In these patients, the presence and number of cardiac risk factors in combination with the risk of the procedure should be considered for further risk stratification and management. Inter mediate--risk patients might be scheduled for the procedure after an electrocardiogram is performed, and appropriate medical therapy (i.e., statins, low-dose titration of β-blockers, and angiotensin--converting enzyme [ACE] inhibitors for those with systolic dysfunction) is initiated. For those patients with a moderate or poor functional capacity (MET <4) scheduled for a high-risk procedure, the identification of cardiac risk factors is the next step.
step 5: clinical cardiac risk factors In patients with a moderate or poor functional capacity and undergoing high-risk surgery, risk factors that should be taken into consideration are a history of MI, angina pectoris, diabetes mellitus, renal dysfunction, a history of transient ischemic attack or cerebrovascular accident, and congestive heart failure (TAbLE 3). In patients with up to 2 clinical cardiac risk factors (intermediate clinical cardiac risk), statins and low-dose titration of β-blockers are recommended prior to surgery, surgery (±5%). Unfortunately, the exact underlying mechanism of PMI is still not clear, but it seems to be the same as in other settings. Coronary plaque rupture, leading to thrombus formation and subsequent vessel occlusion, is considered to be an important cause of acute perioperative coronary syndromes. Surgery itself is a significant stress factor leading to an increased risk of plaque rupture. Two retrospective studies investigated the coronary pathology of fatal PMI and found that half of PMIs are related to plaque rupture. It is thought that the other half of PMIs are related to a sustained myocardial supply/demand imbalance due to tachycardia and increased myocardial contractility in patients with significant CAD.
step 1 The first step is the assessment of the urgency of the surgical procedure. If urgent surgery is the case, patients will go directly for surgery.
step 2: active cardiac disease The next step is the identification of active cardiac disease. This includes recent (within the previous 30 days) MI and residual ischemia, unstable angina pectoris, acute heart failure, significant cardiac arrhythmias, and symptomatic valvular heart disease (TAbLE 1). In case of active or unstable cardiac conditions, the patient should be referred immediately for evaluation and treatment prior to surgery. step 3: surgical risk Surgical procedures can be classified to be associated with a low (<1%), intermediate (1%-5%), or high risk (>5%) for the development of perioperative adverse cardiac events (cardiac death and MI) within 30 days after surgery (TAbLE 2) . Patients undergoing vascular surgery are generally at a greater cardiac risk than patients undergoing any other type of surgery. If the estimated cardiac risk of the procedure is low, it is recommended to proceed with the planned surgical procedure and provide recommendations on lifestyle and medical therapy according to the guidelines to improve a long-term outcome.
step 4: functional capacity The new guidelines recommend the assessment of functional capacity as a pivotal step in preoperative cardiac risk assessment. Functional capacity is measured in meta bolic equivalents (METs). Poor functional 2 β-blockers are recommended in high-risk surgery (IB). 3 Continuation of β-blockers is recommended in patients previously treated with β-blockers because of ischemic heart disease, arrhythmias, or hypertension (IC). 4 β-blockers should be considered in patients scheduled for inter mediate-risk surgery (IIaB). 5 Continuation in patients previously treated with β-blockers because of chronic heart failure with systolic dysfunction is recommended (IIaC). 6 β-blockers may be considered in patients scheduled for low-risk surgery with risk factor(s) (IIbB). 7 β-blockers are not recommended in patients scheduled for low-risk surgery without risk factor(s) (IIIB).
statins Statins are widely prescribed in patients with or at risk for CAD because of their effectiveness in lowering serum cholesterol concentrations through 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition. Beyond the lipid -lowering effect of statins alone, evidence suggests that the more immediate benefits are related to the so called pleiotropic effects of statins. These pleiotropic effects are thought to include improved endothelial function, enhanced stability of atherosclerotic plaques, decreased oxidative stress, and decreased vascular inflammation.
7 These effects of statins may consequently prevent plaque rupture and subsequent MI in the proinflammatory and prothrombotic environment of the perioperative period. The new ESC guidelines give statins the key role in the prevention of perioperative cardiac events. Therefore, a preoperative screening visit should be considered an excellent opportunity not only for perioperative cardiac risk reduction with statins but also a longterm cardiac risk reduction.
Recommendations 1 It is recommended that statins be started in high-risk surgery, optimally between 30 days and at least 1 week before surgery (IB). 2 It is recommended that statins be continued perioperatively (IC).
Acetylsalicylic acid The role of antiplatelet therapy for the prevention of perioperative cardiac events remains controversial. The possible antithrombotic benefits of antiplatelet therapy on perioperative cardiac outcome should be weighed against the possibly increased bleeding risk of its use. However, in general, it is recommended to continue antiplatelet therapy throughout the perioperative period.
Recommendations 1 Continuation of acetylsalicylic acid (ASA) in patients previously treated with ASA should be considered in the perioperative period (IIaB).
In patients with extensive stress-inducible myocardial ischemia, the very high cardiac risk of the planned surgical procedure and the possible harms of not performing a surgery (i.e., risk of rupture in patients with abdominal aortic aneurysm) have to be individually considered. Optimal medical treatment including β-blockers and statins may not provide sufficient cardioprotection. If preoperative revascularization is considered after multidisciplinary consultation, it must be taken into account that the surgical procedure must be postponed at least 2 weeks for balloon angioplasty, 3 months for bare-metal coronary stent placement, and 12 months for drug -eluting coronary stent placement.
Perioperative cardiovascular medication recommendations β-blockers The classic idea of the benefit of β-blocking agents in the perioperative period is their effect on restoring the oxygen supply/demand mismatch. Additional cardioprotective effects are redistribution of coronary blood flow to the subendocardium, plaque stabilization, and an increase in the threshold for ventricular fibrillation. β-adrenergic receptor antagonists (β-blockers) are divided into β 1 -selective and nonselective (β 1 and β 2 ) adrenoreceptor blockers. Atenolol, metoprolol, and bisoprolol, all β 1 -selective blockers, are commonly used for perioperative care.
The specific issue of whether to use β-blockers perioperatively in patients undergoing noncardiac surgery has raised controversies in the past few years. Especially since the publication of the POISE study and the subsequent meta-analysis by Bangalore et al., there has been ongoing debate on the usefulness and safety of perioperative β-blocker therapy. 3,4 Current ESC guidelines have comparable recommendations for perioperative β-blockers use compared with the American Society of Cardiology/American Heart Association guidelines. 5,6 β-blockers are recommended for patients with high cardiac risk based on multiple clinical cardiac risk factors and stress-induced myocardial ischemia. Furthermore, β-blocker therapy is probably reasonable for patients at inter mediate risk, scheduled for high-and intermediate-risk surgery. Acute initiation of high--dose β-blocker therapy should be avoided. Importantly, the guidelines strongly recommend dose titration of β-blockers, which requires treatment initiation optimally 30 days and at least 1 week before surgery. It is recommended to start with a daily dose of 2.5 mg of bisoprolol or 50 mg of metoprolol succinate, and if necessary, adjust the dose before surgery to achieve a resting heart rate between 60 and 70 beats per minute with systolic blood pressure >100 mmHg.
Recommendations 1 β-blockers are recommended in patients who have known ischemic heart disease or myocardial ischemia according to preoperative testing (IB).
2 Discontinuation of ASA therapy in patients previously treated with ASA should be considered only in those in whom hemo stasis is difficult to control during surgery (IIaB). Conclusions This review is a summary of the most important points of the new ESC guidelines for perioperative cardiac risk reduction. Patients undergoing noncardiac surgery have an increased risk of cardiovascular perioperative morbidity and mortality. Preoperative management aims at optimizing the patient's condition by identification and modification of underlying cardiac risk factors and diseases. Systemic medical therapy with β-blockers and statins is currently one of the cornerstones of individualized perioperative management. It should be realized that the preoperative screening of patients does not only offer a unique opportunity to modify the perioperative cardiac risk but also provides a golden opportunity to modify the long-term cardiac risk.
